Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 29 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.97 Insider Own1.11% Shs Outstand3.43M Perf Week-17.80%
Market Cap1.18M Forward P/E- EPS next Y-5.51 Insider Trans0.00% Shs Float2.79M Perf Month-87.33%
Income- PEG- EPS next Q-1.26 Inst Own7.79% Short Float / Ratio0.28% / 0.07 Perf Quarter-89.43%
Sales0.00M P/S- EPS this Y43.40% Inst Trans- Short Interest0.01M Perf Half Y-76.21%
Book/sh-0.86 P/B- EPS next Y-6.00% ROA- Target Price- Perf Year-75.87%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.32 - 3.39 Perf YTD-80.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.89% Beta-0.51
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.00% ATR0.22
Employees9 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)14.83 Volatility14.08% 21.47%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close0.34
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume109.06K Price0.34
Recom3.00 SMA20-80.20% SMA50-85.90% SMA200-83.79% Volume0 Change0.00%
Nov-29-23 05:26PM
Nov-28-23 05:21PM
Sep-18-23 04:05PM
Aug-21-23 08:00AM
Jul-03-23 04:05PM
08:00AM Loading…
Jun-20-23 08:00AM
Jun-05-23 08:00AM
May-15-23 04:15PM
Apr-14-23 09:55AM
Mar-31-23 04:28PM
Mar-20-23 08:00AM
Feb-24-23 08:00AM
Dec-14-22 08:30AM
Dec-09-22 04:05PM
Nov-14-22 08:00AM
12:10PM Loading…
Nov-08-22 12:10PM
Nov-03-22 08:22AM
Oct-25-22 08:00AM
Oct-03-22 09:00AM
Sep-14-22 08:00AM
Aug-29-22 04:05PM
Aug-26-22 08:00AM
Aug-11-22 05:20PM
Aug-08-22 04:05PM
Aug-04-22 09:21AM
Jun-23-22 08:00AM
May-31-22 08:00AM
May-12-22 04:10PM
Apr-28-22 08:00AM
05:44PM Loading…
Mar-31-22 05:44PM
Mar-25-22 08:00AM
Feb-28-22 07:30AM
Feb-03-22 08:00AM
Jan-06-22 08:00AM
Dec-20-21 03:18PM
Nov-17-21 04:18PM
Nov-15-21 04:15PM
Nov-09-21 04:05PM
Nov-05-21 04:05PM
Nov-03-21 08:00AM
Nov-02-21 04:31PM
Oct-07-21 09:11AM
Oct-01-21 08:00AM
Sep-10-21 05:58PM
Aug-24-21 08:00AM
Aug-10-21 08:00AM
Jun-03-21 04:05PM
May-26-21 04:05PM
May-11-21 04:39PM
Apr-28-21 08:00AM
Apr-23-21 08:00AM
Apr-02-21 04:05PM
Mar-23-21 04:05PM
Mar-17-21 08:00AM
Mar-15-21 08:30AM
Mar-05-21 08:30AM
Jan-25-21 04:05PM
Jan-12-21 04:22PM
Dec-15-20 08:00AM
Dec-10-20 08:30AM
Dec-08-20 04:05PM
Nov-20-20 09:05AM
Nov-12-20 04:53PM
Sep-15-20 08:00AM
Sep-11-20 04:29PM
Aug-27-20 08:30AM
Aug-19-20 04:10PM
Aug-18-20 04:10PM
Aug-06-20 02:01PM
Jul-22-20 08:00AM
Jul-01-20 08:00AM
Jun-04-20 08:00AM
Jun-03-20 08:00AM
May-23-20 03:27PM
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.